Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Radiol ; 27(7): 2894-2902, 2017 Jul.
Article in English | MEDLINE | ID: mdl-27830379

ABSTRACT

OBJECTIVES: This study aimed at assessing the effects of an anti-angiogenic treatment, which neutralises vascular endothelial growth factor (VEGF), on tumour heterogeneity. METHODS: Murine glioma cells have been inoculated into the right brain frontal lobe of 16 mice. Anti-VEGF antibody was administered to a first group (n = 8), while a second group (n = 8) received a placebo. Magnetic resonance acquisitions, performed at days 10, 12, 15 and 23 following the implantation, allowed the derivation of a three-dimensional features dataset characterising tumour heterogeneity. Three-dimensional ultramicroscopy and standard histochemistry analysis have been performed to verify in vivo results. RESULTS: Placebo-treated mice displayed a highly-vascularised area at the tumour periphery, a monolithic necrotic core and a chaotic dense vasculature across the entire tumour. In contrast, the B20-treated group did not show any highly vascularised regions and presents a fragmented necrotic core. A significant reduction of the number of vessel segments smaller than 17 µm has been observed. There was no difference in overall tumour volume and growth rate between the two groups. CONCLUSIONS: Region-specific analysis revealed that VEGF inhibition affects only: (1) highly angiogenic compartments expressing high levels of VEGF and characterised by small capillaries, and also (2) the formation and structure of necrotic regions. These effects appear to be transient and limited in time. KEY POINTS: • VEGF inhibition affects only the highly angiogenic region and small capillaries network • VEGF inhibition is transient in time • Tumour volume is not affected by anti-angiogenic treatment • VEGF inhibition also influences the architecture of necrotic regions.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Brain Neoplasms/pathology , Frontal Lobe , Glioma/pathology , Imaging, Three-Dimensional , Magnetic Resonance Imaging/methods , Microscopy/methods , Animals , Brain Neoplasms/drug therapy , Cell Line, Tumor , Glioma/drug therapy , Heterografts , Humans , Mice , Neoplasms, Experimental , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/pathology , Vascular Endothelial Growth Factor A/antagonists & inhibitors
2.
Mol Imaging ; 132014.
Article in English | MEDLINE | ID: mdl-25248521

ABSTRACT

Intratumoral hypoxia changes the metabolism of gliomas, leading to a more aggressive phenotype with increased resistance to radio- and chemotherapy. Hypoxia triggers a signaling cascade with hypoxia-inducible factor (HIF) as a key regulator. We monitored activation of the HIF pathway longitudinally in murine glioma tumors. GL261 cells, stably transfected with a luciferase reporter driven under the control of a promoter comprising the HIF target gene motive hypoxia response element, were implanted either subcutaneously or orthotopically. In vivo experiments were carried out using bioluminescence imaging. Tumors were subsequently analyzed using immunofluorescence staining for hypoxia, endothelial cells, tumor perfusion, and glucose transporter expression. Transient upregulation of the HIF signaling was observed in both subcutaneous and orthotopic gliomas. Immunofluorescence staining confirmed hypoxic regions in subcutaneous and, to a lesser extent, intracranial tumors. Subcutaneous tumors showed substantial necrosis, which might contribute to the decreased bioluminescence output observed toward the end of the experiment. Orthotopic tumors were less hypoxic than subcutaneous ones and did not develop extensive necrotic areas. Although this may be the result of the overall smaller size of orthotopic tumors, it might also reflect differences in the local environment, such as the better intrinsic vascularization of brain tissue compared to the subcutaneous tissue compartment.


Subject(s)
Glioma/metabolism , Glioma/pathology , Luminescent Measurements/methods , Magnetic Resonance Imaging/methods , Animals , Basic Helix-Loop-Helix Transcription Factors/metabolism , Cell Hypoxia , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Genes, Reporter , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Luciferases/metabolism , Luminescent Agents/metabolism , Mice , Mice, Nude , Neoplasm Transplantation , Signal Transduction
3.
J Neurochem ; 113(5): 1210-20, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20345762

ABSTRACT

Retinal degeneration causes the induction of a leukemia inhibitory factor (LIF)-controlled survival pathway which includes Janus kinase/signal transducer and activator of transcription signaling. Lack of LIF prevents activation of this signaling cascade and accelerates disease progression leading to a fast loss of photoreceptor cells. In this study, we show that expression of Janus kinase 3 (Jak3), but not of the other members of the family of Janus kinases, is induced in four different models of retinal degeneration and that LIF is essential and sufficient to activate Jak3 gene expression. We also show that the induction of Jak3 and Lif may not depend directly on cell death but rather on the retinal stress during photoreceptor degeneration. However, despite its dependence on LIF, JAK3 is not essential for LIF-mediated photoreceptor protection or gene expression. Also, absence of JAK3 in knockout mice did not affect immune-related responses in the degenerating retina. JAK3 may therefore play a different, yet unknown, role in the retinal response to photoreceptor injury.


Subject(s)
Janus Kinase 3/metabolism , Leukemia Inhibitory Factor/physiology , Retinal Degeneration/enzymology , Animals , Blotting, Western , Enzyme Activation/physiology , Eye , Fluorescent Antibody Technique , Hypoxia/metabolism , Injections , Janus Kinase 3/genetics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Microglia/physiology , Photoreceptor Cells, Vertebrate/physiology , Recombinant Proteins/pharmacology , Retina/pathology , Retinal Degeneration/pathology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/physiology , Up-Regulation/physiology
4.
Mol Vis ; 15: 1631-7, 2009 Aug 18.
Article in English | MEDLINE | ID: mdl-19693290

ABSTRACT

PURPOSE: Expression of leukemia inhibitory factor (LIF) by a subset of Müller glia cells has recently been implicated in an endogenous survival response to photoreceptor injury in a model of inherited retinal degeneration. To investigate whether such a LIF-controlled survival pathway might be commonly induced upon photoreceptor injury independently of the nature of the toxic stimulus, we analyzed the role of LIF during light-induced retinal degeneration. METHODS: Lif(+/-) and Lif(-/-) mice were exposed to 15,000 lx of white light for 2 h. Retinal morphology and rhodopsin content were analyzed nine days after light exposure. Gene expression studies were done using real-time PCR. Protein levels were determined by western blotting using specific antibodies. RESULTS: A lack of LIF reduced survival of photoreceptor cells after light exposure. In the absence of LIF several genes encoding molecules involved in the Janus kinase/signal transducer and activator of transcription (Jak/STAT) signaling pathway were not activated after light exposure. Presence or absence of LIF did not affect AKT (also known as protein kinase B, PKB) signaling and had only a mild effect on extracellular regulated kinase (ERK) phosphorylation. Stress-induced glial fibrillary acidic protein (GFAP) induction was minimal in the absence of LIF. CONCLUSIONS: Our results suggest that increased retinal expression of LIF is a general response to photoreceptor injury. Independent of the nature of the toxic insult (gene mutation, light), LIF may activate an endogenous rescue pathway that protects viable photoreceptor cells, leading to an increased photoreceptor survival in the stressed retina. This defense system may depend on the Jak/STAT pathway and may involve endothelin 2 (EDN2) but not (or only minimally) AKT and ERK1,2 signaling.


Subject(s)
Leukemia Inhibitory Factor/metabolism , Light , Photoreceptor Cells, Vertebrate/pathology , Photoreceptor Cells, Vertebrate/radiation effects , Retinal Degeneration/pathology , Retinal Degeneration/prevention & control , Animals , Gene Expression Regulation/radiation effects , Leukemia Inhibitory Factor/deficiency , Mice , Photoreceptor Cells, Vertebrate/metabolism , STAT3 Transcription Factor/metabolism , Signal Transduction/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...